The hypothesis that altered dopamine function is a major factor in the
etiology of schizophrenia has persisted for some time, and changes in
other neurochemical systems are strongly implicated as well. These fi
ndings are supported by the recent development of new, effective antip
sychotic agents, such as clozapine and risperidone, whose actions are
attributed to their combined serotonin and dopamine antagonism. In add
ition to their clinical efficacy, these agents are associated with sub
stantially fewer extrapyramidal adverse effects. Continued research to
identify the neurochemical alterations of psychotic diseases will und
oubtedly have a favorable impact on the development of improved therap
eutic regimens.